E-LIB Suche - Ergebnisse für: Wierda, William G.

1

Characteristics Associated With Response to Lisocabtagene M..:

Wierda, William G. ; Maloney, David G. ; Kenderian, Saad S....
Clinical Lymphoma Myeloma and Leukemia. 24 (2024) - p. S180 , 2024

Link: https://doi.org/10.1016/..

2

Chronic lymphocytic leukaemia:

Jain, Nitin ; Wierda, William G ; O'Brien, Susan
The Lancet. 404 (2024) 10453 - p. 694-706 , 2024

Link: https://doi.org/10.1016/..

3

A phase 1/2 study of mini-hyper-CVD plus venetoclax in pati..:

Short, Nicholas J. ; Jabbour, Elias ; Jain, Nitin...
Blood Advances. 8 (2024) 4 - p. 909-915 , 2024

Link: https://doi.org/10.1182/..

4

LP-118 is a novel B-cell lymphoma 2 / extra-large inhibitor..:

Ravikrishnan, Janani ; Diaz-Rohena, Daisy Y. ; Muhowski, Elizabeth...
Haematologica. , 2024

Link: https://doi.org/10.3324/..

5

CLL-269 Pirtobrutinib in Relapsed/Refractory CLL/SLL: Resul..:

Wierda, William G. ; Eyre, Toby A. ; Lech-Maranda, Ewa...
Clinical Lymphoma Myeloma and Leukemia. 24 (2024) - p. S350 , 2024

Link: https://doi.org/10.1016/..

6

Characteristics Associated With Response to Lisocabtagene M..:

Wierda, William G. ; Maloney, David G. ; Kenderian, Saad S....
Clinical Lymphoma Myeloma and Leukemia. 24 (2024) - p. S155 , 2024

Link: https://doi.org/10.1016/..

7

Outcomes in High-Risk Subgroups After Fixed-Duration Ibruti..:

Wierda, William G. ; Jacobs, Ryan ; Barr, Paul M....
Clinical Lymphoma Myeloma and Leukemia. 24 (2024) - p. S179 , 2024

Link: https://doi.org/10.1016/..

8

A multicenter study of venetoclax-based treatment for patie..:

Hampel, Paul J. ; Swaminathan, Mahesh ; Rogers, Kerry A....
Blood Advances. 8 (2024) 10 - p. 2342-2350 , 2024

Link: https://doi.org/10.1182/..

9

Transcriptomic and proteomic differences in BTK-WT and BTK-..:

Aslan, Burcu ; Manyam, Ganiraju ; Iles, Lakesla R....
Blood Advances. 8 (2024) 17 - p. 4487-4501 , 2024

Link: https://doi.org/10.1182/..

10

CLL-057 Outcomes in High-Risk Subgroups After Fixed-Duratio..:

Wierda, William G. ; Jacobs, Ryan ; Barr, Paul M....
Clinical Lymphoma Myeloma and Leukemia. 24 (2024) - p. S342 , 2024

Link: https://doi.org/10.1016/..

11

Six-year follow-up and subgroup analyses of a phase 2 trial..:

Stilgenbauer, Stephan ; Tausch, Eugen ; Roberts, Andrew W....
Blood Advances. 8 (2024) 8 - p. 1992-2004 , 2024

Link: https://doi.org/10.1182/..

12

Pirtobrutinib in Relapsed/Refractory CLL/SLL: Results From ..:

Wierda, William G. ; Eyre, Toby A. ; Lech-Maranda, Ewa...
Clinical Lymphoma Myeloma and Leukemia. 24 (2024) - p. S181 , 2024

Link: https://doi.org/10.1016/..

13

Pirtobrutinib, a highly selective, non-covalent (reversible..:

Wierda, William G ; Shah, Nirav N ; Cheah, Chan Y...
The Lancet Haematology. 11 (2024) 9 - p. e682-e692 , 2024

Link: https://doi.org/10.1016/..

14

Lisocabtagene Maraleucel (liso-cel) in Patients (Pt) With R..:

Shah, Nirav N. ; Siddiqi, Tanya ; Maloney, David G....
Transplantation and Cellular Therapy. 30 (2024) 2 - p. S353-S354 , 2024

Link: https://doi.org/10.1016/..

15

CLL-184 Characteristics Associated With Response to Lisocab..:

Wierda, William G. ; Maloney, David G. ; Kenderian, Saad S....
Clinical Lymphoma Myeloma and Leukemia. 24 (2024) - p. S346 , 2024

Link: https://doi.org/10.1016/..